海南海药(000566) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥545,255,859.45, representing an increase of 8.48% compared to ¥502,626,221.61 in the same period last year[9] - The net profit attributable to shareholders was -¥151,134,429.84, a decrease of 49.49% from -¥101,101,720.41 year-on-year[9] - The basic earnings per share decreased by 53.90% to -¥0.1165 from -¥0.0757 in the same period last year[9] - The company reported a net loss of CNY 593,132,246.50, representing a 34.19% increase in losses compared to the previous year[17] - The net profit for the current period was a loss of CNY 160,927,943.94, compared to a loss of CNY 105,352,005.43 in the previous period, indicating a worsening of approximately 52.7%[45] - The total comprehensive income for the current period was a loss of CNY 160,723,723.78, compared to a loss of CNY 104,397,126.47 in the previous period, reflecting a deterioration of approximately 54%[46] - The net profit for the current period is -113,612,942.06, compared to -50,717,930.51 in the previous period, indicating a significant increase in losses[49] - Operating profit for the current period is -113,665,677.77, compared to -67,609,207.35 in the previous period, reflecting a worsening operational performance[49] Cash Flow - The net cash flow from operating activities improved significantly to ¥48,216,675.34, compared to -¥99,757,670.91 in the previous year, marking a 148.33% increase[9] - Cash flow from operating activities shows a net inflow of 48,216,675.34, a recovery from a net outflow of -99,757,670.91 in the previous period[53] - The net cash flow from investing activities increased by 277.48% to CNY 310,672,285.03, mainly due to a reduction in purchased time deposits compared to the previous year[18] - Total cash flow from investing activities is a net inflow of 310,672,285.03, compared to a net outflow of -175,042,888.02 in the previous period, indicating improved investment cash flow[54] - Cash flow from financing activities resulted in a net outflow of -543,999,549.30, compared to a net inflow of 499,997,356.07 in the previous period, showing increased cash outflow for financing[54] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,707,734,194.32, down 5.56% from ¥10,279,231,596.61 at the end of the previous year[9] - The total liabilities decreased to CNY 4,760,620,084.07 from CNY 5,183,151,954.30, a decline of about 8.1%[41] - The company's equity attributable to shareholders decreased from ¥3,706,114,482.42 to ¥3,542,645,937.12, a decline of about 4.41%[37] - Current liabilities decreased from ¥5,017,198,409.09 to ¥4,762,317,037.40, a reduction of about 5.06%[36] - Long-term borrowings decreased from ¥828,243,247.92 to ¥705,243,247.92, a decrease of approximately 14.87%[36] - Total liabilities decreased from ¥6,307,612,628.58 to ¥5,899,766,738.37, a decline of around 6.46%[36] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,558[13] - The largest shareholder, Hainan Huadong Industrial Co., Ltd., holds 22.89% of the shares, totaling 296,989,889 shares[13] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[14] - The company completed the cancellation of 38,614,138 repurchased shares on March 29, 2021[21] Operational Highlights - The company has completed the construction of two production lines for 100 tons of cephalosporin crude products, with a remaining budget of ¥3.0336 million permanently supplementing working capital[25] - The company has no new product launches or significant market expansion strategies mentioned in the report[37] Financial Standards and Compliance - The company has implemented new leasing standards starting from 2021, which required adjustments to the financial statements[59] - The impact of the new leasing standard on the consolidated balance sheet as of January 1, 2021, shows a decrease in fixed assets by CNY 124,115,494.29, while the right-of-use assets increased by the same amount[64] - The company did not apply retrospective adjustments for prior comparative data under the new leasing standard starting from 2021[68] - The first quarter report for 2021 was not audited, indicating that the figures presented are preliminary and subject to change[68] Other Financial Metrics - The company reported a significant increase in financial expenses by 84.21% to CNY 42,313,374.75, due to the restoration of previously offset capitalized interest income[18] - Research and development expenses increased to CNY 14,496,556.52 from CNY 11,941,161.06, marking an increase of about 21.5%[44] - The company incurred credit impairment losses of -4,996,571.49, compared to -3,685,213.46 in the previous period, indicating increased credit risk[49] - The company received tax refunds amounting to 723,572.58, down from 988,207.29 in the previous period, reflecting a decrease in tax recovery[53]